Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www-thieme-connect-de.accesdistant.sorbonne-universite.fr/rss/thieme/en/10.1055-s-00000069.xml
Download PDF
Semin Liver Dis 2022; 42(03): 341-361
DOI: 10.1055/a-1886-5909
DOI: 10.1055/a-1886-5909
Review Article
Mastering Core Recommendations during HEPAtology ROUNDS in Patients with Advanced Chronic Liver Disease
Funding None.
Abstract
Efficient and thorough care of hospitalized patients with advanced chronic liver disease is of utter importance to improve outcomes and optimize quality of life. This requires understanding current evidence and best practices. To facilitate focus on up-to-date knowledge and a practical approach, we have created the HEPA-ROUNDS mnemonic while outlining a practical review of the literature with critical appraisal for the busy clinician. The HEPA-ROUNDS mnemonic provides a structured approach that incorporates critical concepts in terms of prevention, management, and prognostication of the most common complications frequently encountered in patients with advanced chronic liver disease. In addition, implementing the HEPA-ROUNDS mnemonic can facilitate education for trainees and staff caring for patients with advanced chronic liver disease.
Keywords
Advanced Chronic Liver Disease - cirrhosis - hepatorenal syndrome - hyponatremia - albumin - prophylaxisAuthors' Contributions
Mauricio Garcia-Saenz-de-Sicilia, Lolwa Al-Obaid, Dempsey Hughes, and Andres Duarte-Rojo contributed with writing and editing of the manuscript. Mauricio Garcia-Saenz-de-Sicilia, Dempsey Hughes and Andres Duarte-Rojo also contributed with intellectual design, and approved final version of the manuscript.
Publication History
Accepted Manuscript online:
28 June 2022
Article published online:
24 August 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 D'Amico G, Pasta L, Morabito A. et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39 (10) 1180-1193
- 2
de Franchis R,
Bosch J,
Garcia-Tsao G,
Reiberger T,
Ripoll C.
Baveno VII Faculty.
Baveno VII - renewing consensus in portal hypertension. J Hepatol 2022; 76 (04) 959-974
MissingFormLabel
- 3
O'Leary JG,
Greenberg CS,
Patton HM,
Caldwell SH.
AGA clinical practice update: coagulation in cirrhosis. Gastroenterology 2019; 157
(01) 34-43.e1
MissingFormLabel
- 4
Zermatten MG,
Fraga M,
Moradpour D.
et al.
Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis.
Hepatology 2020; 71 (06) 2135-2148
MissingFormLabel
- 5
Tripodi A,
Mannucci PM.
The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
MissingFormLabel
- 6
Lisman T,
Bongers TN,
Adelmeijer J.
et al.
Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite
reduced functional capacity. Hepatology 2006; 44 (01) 53-61
MissingFormLabel
- 7 Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59 (02) 265-270
- 8 Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94 (10) 2801-2803
- 9 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost 2017; 117 (01) 139-148
- 10 Dhar A, Mullish BH, Thursz MR. Anticoagulation in chronic liver disease. J Hepatol 2017; 66 (06) 1313-1326
- 11 Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther 2010; 31 (03) 366-374
- 12 Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thromb Res 2014; 134 (06) 1220-1223
- 13 Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA technical review on coagulation in cirrhosis. Gastroenterology 2021; 161 (05) 1630-1656
- 14 Stotts MJ, Davis JPE, Shah NL. Coagulation testing and management in liver disease patients. Curr Opin Gastroenterol 2020; 36 (03) 169-176
- 15 Giannini EG, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology 2014; 60 (04) 1442
- 16 Harrison MF. The misunderstood coagulopathy of liver disease: a review for the acute setting. West J Emerg Med 2018; 19 (05) 863-871
- 17 Somani V, Amarapurkar D, Shah A. Thromboelastography for assessing the risk of bleeding in patients with cirrhosis-moving closer. J Clin Exp Hepatol 2017; 7 (04) 284-289
- 18 Segal JB, Dzik WH. Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45 (09) 1413-1425
- 19
Terrault N,
Chen YC,
Izumi N.
et al.
Avatrombopag before procedures reduces need for platelet transfusion in patients with
chronic liver disease and thrombocytopenia. Gastroenterology 2018; 155 (03) 705-718
MissingFormLabel
- 20 Tateishi R, Seike M, Kudo M. et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol 2019; 54 (02) 171-181
- 21 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2017; 65 (01) 310-335
- 22 Adam EH, Möhlmann M, Herrmann E. et al. Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis. World J Gastroenterol 2020; 26 (17) 2097-2110
- 23 Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89 (02) 228-232
- 24 Seeßle J, Löhr J, Kirchner M, Michaelis J, Merle U. Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and non-ACLF patients. BMC Gastroenterol 2020; 20 (01) 271
- 25
Kumar M,
Ahmad J,
Maiwall R.
et al.
Thromboelastography-guided blood component use in patients with cirrhosis with nonvariceal
bleeding: a randomized controlled trial. Hepatology 2020; 71 (01) 235-246
MissingFormLabel
- 26
De Pietri L,
Bianchini M,
Montalti R.
et al.
Thrombelastography-guided blood product use before invasive procedures in cirrhosis
with severe coagulopathy: a randomized, controlled trial. Hepatology 2016; 63 (02)
566-573
MissingFormLabel
- 27
Vilstrup H,
Amodio P,
Bajaj J.
et al.
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American
Association for the Study of Liver Diseases and the European Association for the Study
of the Liver. Hepatology 2014; 60 (02) 715-735
MissingFormLabel
- 28 Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol 2015; 13 (12) 2048-2061
- 29 Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs 2019; 79 (Suppl 1): 5-9
- 30 Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000; 32 (06) 1035-1038
- 31 Bajaj JS, Lauridsen M, Tapper EB. et al. Important unresolved questions in the management of hepatic encephalopathy: an ISHEN consensus. Am J Gastroenterol 2020; 115 (07) 989-1002
- 32 Hanna A, Gill I, Imam Z, Halalau A, Jamil LH. Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy. BMJ Open Gastroenterol 2021; 8 (01) 8
- 33 Rose CF. What's new in our understanding of the pathogenesis of hepatic encephalopathy?. Clin Liver Dis (Hoboken) 2017; 10 (02) 29-31
- 34 Strauss E, Tramote R, Silva EP. et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39 (06) 542-545
- 35 Rose CF, Amodio P, Bajaj JS. et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 2020; 73 (06) 1526-1547
- 36 Arroyo V, Moreau R, Kamath PS. et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers 2016; 2: 16041
- 37 Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med 2020; 382 (22) 2137-2145
- 38 Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med 2014; 174 (11) 1727-1733
- 39 Bass NM, Mullen KD, Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12) 1071-1081
- 40 Bureau C, Thabut D, Jezequel C. et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med 2021; 174 (05) 633-640
- 41 Caraceni P, Vargas V, Solà E. et al; Liverhope Consortium. The use of rifaximin in patients with cirrhosis. Hepatology 2021; 74 (03) 1660-1673
- 42 Gluud LL, Dam G, Les I. et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2017; 5: CD001939
- 43 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev 2018; 5: CD012410
- 44 Jain A, Sharma BC, Mahajan B. et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology 2022; 75 (05) 1194-1203
- 45 Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28 (01) 26-42
- 46 Biggins SW, Angeli P, Garcia-Tsao G. et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (02) 1014-1048
- 47 Moreau R, Jalan R, Gines P. et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
- 48 Kanwal F, Tapper EB, Ho C. et al. Development of quality measures in cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2019; 69 (04) 1787-1797
- 49 Fernández J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 2016; 63 (06) 2019-2031
- 50 Martínez J, Hernández-Gea V, Rodríguez-de-Santiago E. et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. J Hepatol 2021; 75 (02) 342-350
- 51 Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29 (06) 1655-1661
- 52 Hou MC, Lin HC, Liu TT. et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004; 39 (03) 746-753
- 53 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 2011; 34 (05) 509-518
- 54 Fernández J, Ruiz del Arbol L, Gómez C. et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006; 131 (04) 1049-1056 , quiz 1285
- 55 Llach J, Rimola A, Navasa M. et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16 (03) 724-727
- 56 Fernández J, Navasa M, Planas R. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133 (03) 818-824
- 57 Moreau R, Elkrief L, Bureau C. et al; NORFLOCIR Trial Investigators. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology 2018; 155 (06) 1816-1827.e9
- 58 Yim HJ, Suh SJ, Jung YK. et al. Daily norfloxacin vs. weekly ciprofloxacin to prevent spontaneous bacterial peritonitis: a randomized controlled trial. Am J Gastroenterol 2018; 113 (08) 1167-1176
- 59 Lontos S, Shelton E, Angus PW. et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis 2014; 15 (05) 260-267
- 60 Komolafe O, Roberts D, Freeman SC. et al. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: CD013125
- 61 Facciorusso A, Papagiouvanni I, Cela M, Buccino VR, Sacco R. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver Int 2019; 39 (08) 1448-1458
- 62 Goel A, Rahim U, Nguyen LH, Stave C, Nguyen MH. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther 2017; 46 (11-12): 1029-1036
- 63 Wang W, Yang J, Liu C. et al. Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis. Eur J Gastroenterol Hepatol 2019; 31 (08) 905-910
- 64 Assem M, Elsabaawy M, Abdelrashed M. et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int 2016; 10 (02) 377-385
- 65 Hanouneh MA, Hanouneh IA, Hashash JG. et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46 (08) 709-715
- 66 Ginés P, Rimola A, Planas R. et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4, Pt 1): 716-724
- 67 Piroth L, Pechinot A, Di Martino V. et al. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis 2014; 14: 287
- 68 Mücke MM, Mücke VT, Graf C. et al. Efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis: a systematic review and meta-analysis. Clin Transl Gastroenterol 2020; 11 (08) e00223
- 69 Mücke MM, Mayer A, Kessel J. et al. Quinolone and multidrug resistance predicts failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis 2020; 70 (09) 1916-1924
- 70 Elfert A, Abo Ali L, Soliman S, Ibrahim S, Abd-Elsalam S. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2016; 28 (12) 1450-1454
- 71 Piano S, Fasolato S, Salinas F. et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology 2016; 63 (04) 1299-1309
- 72 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
- 73 Ferraioli G, Wong VW, Castera L. et al. Liver ultrasound elastography: an update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol 2018; 44 (12) 2419-2440
- 74 Vizzutti F, Arena U, Romanelli RG. et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45 (05) 1290-1297
- 75 Duarte-Rojo A, Heimbach JK, Borja-Cacho D. et al. Usefulness of controlled attenuation parameter and liver stiffness measurement for the identification of extended-criteria donors and risk-assessment in liver transplantation. Transplantation 2022; 106 (02) 318-327
- 76 Berzigotti A, Seijo S, Arena U. et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013; 144 (01) 102-111.e1
- 77 Shi KQ, Fan YC, Pan ZZ. et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013; 33 (01) 62-71
- 78 Procopet B, Berzigotti A, Abraldes JG. et al. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatol 2015; 62 (05) 1068-1075
- 79 Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol–a medical treatment for portal hypertension?. Lancet 1980; 2 (8187): 180-182
- 80 Mauro E, Gadano A. What's new in portal hypertension?. Liver Int 2020; 40 (Suppl 1): 122-127
- 81 Thabut D, Bureau C, Layese R. et al; ANRS CO12 CirVir Group. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 2019; 156 (04) 997-1009.e5
- 82 Tripathi D, Ferguson JW, Kochar N. et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009; 50 (03) 825-833
- 83 Hwang JH, Shergill AK, Acosta RD. et al; American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc 2014; 80 (02) 221-227
- 84 Villanueva C, Albillos A, Genescà J. et al. β Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019; 393 (10181): 1597-1608
- 85 Sersté T, Francoz C, Durand F. et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55 (04) 794-799
- 86 Kalambokis GN, Christodoulou D, Baltayiannis G, Christou L. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites. Hepatology 2016; 64 (05) 1806-1808
- 87 Mandorfer M, Bota S, Schwabl P. et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146 (07) 1680-1690.e1
- 88 Facciorusso A, Roy S, Livadas S. et al. Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites. Dig Dis Sci 2018; 63 (07) 1737-1746
- 89 Onali S, Kalafateli M, Majumdar A. et al. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver Int 2017; 37 (09) 1334-1344
- 90 Calès P, Bertrais S, Boursier J, Fouchard I, Oberti F. SNIFF 16 Group. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up. Liver Int 2021; 41 (01) 168-179
- 91 Scheiner B, Parada-Rodriguez D, Bucsics T. et al. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol 2017; 52 (09) 1008-1015
- 92 Chirapongsathorn S, Valentin N, Alahdab F. et al. Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14 (08) 1096-1104.e9
- 93 Bhutta AQ, Garcia-Tsao G, Reddy KR. et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther 2018; 47 (01) 78-85
- 94 Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C. et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol 2020; 73 (06) 1404-1414
- 95 Thevenot T, Mouhat B, Cervoni JP, Chopard R. The dual role of non-selective beta-blockers in cirrhotic patients: How do we know when Dr Jekyll turns into Mr Hyde?. Liver Int 2021; 41 (05) 1166-1167
- 96 Bernardi M, Angeli P, Claria J. et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 2020; 69 (06) 1127-1138
- 97 Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018; 38 (04) 570-580
- 98 Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339 (08) 533-541
- 99 Pozzi M, Osculati G, Boari G. et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106 (03) 709-719
- 100 Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113 (02) 579-586
- 101 European Association for the Study of the Liver, Electronic address, easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460
- 102 Ginès A, Fernández-Esparrach G, Monescillo A. et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111 (04) 1002-1010
- 103 Ginés P, Arroyo V, Quintero E. et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93 (02) 234-241
- 104 Ginès P, Titó L, Arroyo V. et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94 (06) 1493-1502
- 105 Tan HK, James PD, Wong F. Albumin may prevent the morbidity of paracentesis-induced circulatory dysfunction in cirrhosis and refractory ascites: a pilot study. Dig Dis Sci 2016; 61 (10) 3084-3092
- 106 Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013; 11 (02) 123-30.e1
- 107 Sort P, Navasa M, Arroyo V. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341 (06) 403-409
- 108 Poca M, Concepción M, Casas M. et al. Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2012; 10 (03) 309-315
- 109 Dionigi E, Garcovich M, Borzio M. et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gastroenterol 2017; 112 (04) 588-596
- 110 O'Leary JG, Reddy KR, Garcia-Tsao G. et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology 2018; 67 (06) 2367-2374
- 111 Garcia-Martinez R, Andreola F, Mehta G. et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol 2015; 62 (04) 799-806
- 112 Fernández J, Clària J, Amorós A. et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 2019; 157 (01) 149-162
- 113 Thévenot T, Bureau C, Oberti F. et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015; 62 (04) 822-830
- 114 Best LM, Freeman SC, Sutton AJ. et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2019; 9: CD013103
- 115 Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev 2019; 6: CD004039
- 116 China L, Freemantle N, Forrest E. et al; ATTIRE Trial Investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021; 384 (09) 808-817
- 117 Wong YJ, Qiu TY, Tam YC, Mohan BP, Gallegos-Orozco JF, Adler DG. Efficacy and safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 2020; 52 (10) 1137-1142
- 118 Weiss E, Paugam-Burtz C, Jaber S. Shock etiologies and fluid management in liver failure. Semin Respir Crit Care Med 2018; 39 (05) 538-545
- 119 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350 (22) 2247-2256
- 120 Caironi P, Tognoni G, Masson S. et al; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370 (15) 1412-1421
- 121 Philips CA, Maiwall R, Sharma MK. et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int 2021; 15 (04) 983-994
- 122 Lee TH, Kuo G, Chang CH. et al. Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: an updated systematic review and meta-analysis. PLoS One 2021; 16 (12) e0260312
- 123 Caraceni P, Riggio O, Angeli P. et al; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018; 391 (10138): 2417-2429
- 124 Caraceni P, Tufoni M, Zaccherini G. et al; ANSWER Study Investigators. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol 2021; 74 (02) 340-349
- 125 Solà E, Solé C, Simón-Talero M. et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol 2018; 69 (06) 1250-1259
- 126 Tandon P, James MT, Abraldes JG, Karvellas CJ, Ye F, Pannu N. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: a retrospective population-based cohort study. PLoS One 2016; 11 (08) e0160394
- 127 Angeli P, Ginès P, Wong F. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62 (04) 968-974
- 128 Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018; 4 (01) 23
- 129 Asrani SK, Kim WR, Heimbach J. et al. Acute tubular necrosis is present in the majority of patients undergoing liver transplantation. Hepatology 2011; 54: 629
- 130 Patidar KR, Kang L, Bajaj JS, Carl D, Sanyal AJ. Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology 2018; 68 (01) 224-233
- 131 Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol 2019; 71 (04) 811-822
- 132 Huelin P, Piano S, Solà E. et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol Hepatol 2017; 15 (03) 438-445.e5
- 133 Huggins JT, Doelken P, Walters C, Rockey DC. Point-of-care echocardiography improves assessment of volume status in cirrhosis and hepatorenal syndrome. Am J Med Sci 2016; 351 (05) 550-553
- 134 Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011; 58 (06) 928-938
- 135 Sanyal AJ, Boyer TD, Frederick RT. et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther 2017; 45 (11) 1390-1402
- 136 Wong F, Pappas SC, Curry MP. et al; CONFIRM Study Investigators. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 2021; 384 (09) 818-828
- 137 Palmer P, Waleed M, Abdallah M, Melick L, Singal AK. Efficacy and safety of therapies for type 1 hepatorenal syndrome: a systematic review and meta-analysis. Hepatology 2021; 74: 1188-1189
- 138 El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. Front Pharmacol 2021; 12: 675948
- 139 Escorsell A, Bandi JC, Andreu V. et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120 (01) 161-169
- 140 Angeli P, Rodríguez E, Piano S. et al; CANONIC Study Investigators of EASL-CLIF Consortium. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut 2015; 64 (10) 1616-1622
- 141 Jalan R, Saliba F, Pavesi M. et al; CANONIC Study Investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61 (05) 1038-1047
- 142 Engelmann C, Thomsen KL, Zakeri N. et al. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Crit Care 2018; 22 (01) 254
- 143 Rosenblatt R, Shen N, Tafesh Z. et al. The North American Consortium for the Study of End-Stage Liver Disease - Acute-on-chronic liver failure score accurately predicts survival: an external validation using a national cohort. Liver Transpl 2020; 26 (02) 187-195
- 144 Chan AC, Fan ST. Criteria for liver transplantation in ACLF and outcome. Hepatol Int 2015; 9 (03) 355-359
- 145 Reddy MS, Rajalingam R, Rela M. Liver transplantation in acute-on-chronic liver failure: lessons learnt from acute liver failure setting. Hepatol Int 2015; 9 (04) 508-513
- 146 Kwong AJ, Kim WR, Lake JR. et al. OPTN/SRTR 2019 annual data report: liver. Am J Transplant 2021; 21 (Suppl 2): 208-315
- 147 Lucey MR, Terrault N, Ojo L. et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19 (01) 3-26
- 148 Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17 (Suppl 3): S1-S9
- 149 Charlton M, Levitsky J, Aqel B. et al. International Liver Transplantation Society Consensus Statement on immunosuppression in liver transplant recipients. Transplantation 2018; 102 (05) 727-743
- 150 Tasdogan BE, Ma M, Simsek C, Saberi B, Gurakar A. Update on immunosuppression in liver transplantation. Euroasian J Hepatogastroenterol 2019; 9 (02) 96-101
- 151 Siddiqui MB, Patel S, Bhati C. et al. Range of normal serum aminotransferase levels in liver transplant recipients. Transplant Proc 2019; 51 (06) 1895-1901
- 152 Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012; 55 (02) 447-454
- 153 Mason AL, Montano-Loza AJ. Systematic investigation of elevated cholestatic enzymes during the third posttransplant month. Liver Transpl 2013; 19 (Suppl 2): S23-S30
- 154 Demetris AJ, Bellamy C, Hübscher SG. et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant 2016; 16 (10) 2816-2835
- 155 Gelb B, Feng S. Management of the liver transplant patient. Expert Rev Gastroenterol Hepatol 2009; 3 (06) 631-647
- 156 Demetris AJ, Adeyi O, Bellamy CO. et al; Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44 (02) 489-501
- 157 Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15 (12) 1662-1670
- 158 Laryea M, Watt KD, Molinari M. et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13 (08) 1109-1114
- 159 Chen LS, Lin HC, Hwang SJ, Lee FY, Hou MC, Lee SD. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. J Gastroenterol Hepatol 1996; 11 (01) 59-64
- 160 Voulgaris T, Karagiannakis D, Siakavellas S. et al. High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. Ann Gastroenterol 2019; 32 (05) 451-456
- 161 Bajaj JS, Acharya C, Fagan A. et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol 2018; 113 (08) 1177-1186
- 162 Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10 (04) 422-427
- 163 Bajaj JS, Zadvornova Y, Heuman DM. et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104 (05) 1130-1134
- 164 Bajaj JS, Ananthakrishnan AN, Hafeezullah M. et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010; 105 (01) 106-113
- 165 Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012; 36 (09) 866-874
- 166 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun 2019; 3 (11) 1510-1519
- 167 Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC. et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol 2010; 16 (46) 5869-5873
- 168 Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology 2022; 162 (04) 1334-1342
- 169 Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K. Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J Gastroenterol 2002; 37 (12) 1028-1034
- 170 Sundaram V, Lim J, Tholey DM. et al. The Braden scale, a standard tool for assessing pressure ulcer risk, predicts early outcomes after liver transplantation. Liver Transpl 2017; 23 (09) 1153-1160
- 171 Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl 2017; 23 (11) 1451-1464
- 172 Palmer LB, Kuftinec G, Pearlman M, Green CH. Nutrition in cirrhosis. Curr Gastroenterol Rep 2019; 21 (08) 38
- 173 European Association for the Study of the Liver. Electronic Address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172-193
- 174 Román E, Poca M, Amorós-Figueras G. et al. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Sci Rep 2021; 11 (01) 20415
- 175 Ruiz-Margáin A, Macías-Rodríguez RU, Duarte-Rojo A, Ríos-Torres SL, Espinosa-Cuevas Á, Torre A. Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study. Dig Liver Dis 2015; 47 (04) 309-314
- 176 Ruiz-Margain A, Xie JJ, Roman-Calleja BM. et al. Phase angle from bioelectrical impedance for the assessment of sarcopenia in cirrhosis with or without ascites. Clin Gastroenterol Hepatol 2021; 19 (09) 1941-1949.e2
- 177 Venu M, Martin E, Saeian K, Gawrieh S. High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation. Liver Transpl 2013; 19 (06) 627-633
- 178 Lai JC, Tandon P, Bernal W. et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (03) 1611-1644
- 179
Simon TG,
King LY,
Chong DQ.
et al.
Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from
two prospective cohort studies. Hepatology 2018; 67 (05) 1797-1806
MissingFormLabel
- 180 Addepally NS, George N, Martinez-Macias R, Garcia-Saenz-de-Sicilia M, Kim WR, Duarte-Rojo A. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis. Dig Dis Sci 2018; 63 (12) 3498-3508
- 181 Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022; 76 (06) 1263-1278
- 182 Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985; 100 (02) 126-131
- 183 Serper M, Tao SY, Kent DS. et al. Inpatient frailty assessment is feasible and predicts nonhome discharge and mortality in decompensated cirrhosis. Liver Transpl 2021; 27 (12) 1711-1722
- 184 Lai JC, Rahimi RS, Verna EC. et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology 2019; 156 (06) 1675-1682
- 185 Groff A, Serper M, Tao S, Bloomer PM, Dunn MA, Duarte-Rojo A. Highest level of mobility predicts mortality in hospitalized patients with decompensated cirrhosis. Hepatology 2021; 74: 1218A
- 186 Dunn MA, Kappus MR, Bloomer PM, Duarte-Rojo A, Josbeno DA, Jakicic JM. Wearables, physical activity, and exercise testing in liver disease. Semin Liver Dis 2021; 41 (02) 128-135
- 187 Yadav A, Chang YH, Carpenter S. et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant 2015; 29 (02) 134-141
- 188 Dang TT, Ebadi M, Abraldes JG. et al. The 6-minute walk test distance predicts mortality in cirrhosis: a cohort of 694 patients awaiting liver transplantation. Liver Transpl 2021; 27 (10) 1490-1492
- 189 Lin FP, Visina JM, Bloomer PM. et al. Prehabilitation-driven changes in frailty metrics predict mortality in patients with advanced liver disease. Am J Gastroenterol 2021; 116 (10) 2105-2117
- 190 Duarte-Rojo A, Bloomer PM, Rogers RJ. et al. Introducing EL-FIT (Exercise and Liver FITness): a smartphone app to prehabilitate and monitor liver transplant candidates. Liver Transpl 2021; 27 (04) 502-512
- 191 Angeli P, Wong F, Watson H, Ginès P. CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44 (06) 1535-1542
- 192 Londoño MC, Guevara M, Rimola A. et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130 (04) 1135-1143
- 193 Biggins SW. Use of serum sodium for liver transplant graft allocation: a decade in the making, now is it ready for primetime?. Liver Transpl 2015; 21 (03) 279-281
- 194 Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342 (21) 1581-1589
- 195 Alukal JJ, John S, Thuluvath PJ. Hyponatremia in cirrhosis: an update. Am J Gastroenterol 2020; 115 (11) 1775-1785
- 196 China L, Freemantle N, Forrest E. et al. Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: data from the ATTIRE trial. Am J Gastroenterol 2021; 116 (11) 2292-2295
- 197 Sigal SH, Amin A, Chiodo III JA, Sanyal A. Management strategies and outcomes for hyponatremia in cirrhosis in the Hyponatremia Registry. Can J Gastroenterol Hepatol 2018; 2018: 1579508
- 198 Pose E, Solà E, Piano S. et al. Limited efficacy of tolvaptan in patients with cirrhosis and severe hyponatremia: real-life experience. Am J Med 2017; 130 (03) 372-375
- 199 Villa E, Cammà C, Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253-1260.e4
- 200 Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34 (01) 26-32
- 201 Shatzel J, Dulai PS, Harbin D. et al. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. J Thromb Haemost 2015; 13 (07) 1245-1253